WO2014118809A1 - Composition pharmaceutique comprenant du linézolide - Google Patents
Composition pharmaceutique comprenant du linézolide Download PDFInfo
- Publication number
- WO2014118809A1 WO2014118809A1 PCT/IS2014/050001 IS2014050001W WO2014118809A1 WO 2014118809 A1 WO2014118809 A1 WO 2014118809A1 IS 2014050001 W IS2014050001 W IS 2014050001W WO 2014118809 A1 WO2014118809 A1 WO 2014118809A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical formulation
- range
- linezolid
- sodium
- tablet
- Prior art date
Links
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 37
- 229960003907 linezolid Drugs 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims abstract description 35
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 32
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 16
- 239000007884 disintegrant Substances 0.000 claims abstract description 12
- 239000000945 filler Substances 0.000 claims abstract description 12
- 239000008109 sodium starch glycolate Substances 0.000 claims abstract description 11
- 229920003109 sodium starch glycolate Polymers 0.000 claims abstract description 11
- 229940079832 sodium starch glycolate Drugs 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 8
- 239000007916 tablet composition Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 18
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 8
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 5
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 19
- 239000000463 material Substances 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- -1 400 Chemical compound 0.000 description 3
- 241001489705 Aquarius Species 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000008202 granule composition Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005490 tosylate group Chemical class 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Definitions
- the present invention is within the field of pharmaceuticals and pertains to particular formulations of the antibiotic linezolid or a salt thereof.
- Linezolid is a synthetic antibiotic of the oxazolidinone class type. The preparation thereof is described in WO 95/07271.
- the chemical formula of the compound is (S)-/V-( ⁇ 3-[3-fluoro-4 (morpholin-4-yl)phenyl]-2-oxo-l,3-oxazolidin-5-yl ⁇ methyl)acetamide, with the structure being shown in Formula I.
- Staphylococcus aureus including hospital-acquired pneumonia, infections of the skin etc.
- Linezolid was first approved for use in 2000 and was the first commercially available oxazolidinone, though others are in development.
- Linezolid exists in different polymorphic forms, at least the forms I, II, III, and IV.
- the current commercially available product, (Zyvox, Zyvoxid; by Pfizer) uses form II, which is described in US patent No. 6,559,305.
- Form IV is described in US 2006/0142283, this form is also claimed by WO 2005/035530 but referred to as Form III.
- the recognised Form III is disclosed in US patent No. 7,714, 128, and is characterised by XRD peaks expressed as 2 ⁇ at about 7.6, 9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9, and 29.9 degrees.
- 2006/0111350 also discloses the different polymorphic forms, and the amorphous form is disclosed in WO 2007/026369.
- a proposed dosage form in this prior art document is of the effervescent type, making use of an effervescent couple which can produce gas bubbles when in contact with water, which helps disrupting the gel layer that forms around Form III crystals.
- the disclosed dosage forms comprise sodium hydrogen carbonate and citric acid as an effervescent couple.
- 2010/026597 discloses multiparticulate compositions, which requires forming a core in the form of a beadlet or pellet, obtained by extrusion and spheronization, where the core comprises linezolid form III. These processes however require special material or equipment or both.
- the present invention provides stable formulations with linezolid or a salt thereof that can be successfully used with different polymorphic forms of the compound, overcoming existing problems with gelling properties and challenges due to bulk properties.
- the invention provides in a first aspect a pharmaceutical tablet formulation comprising linezolid or a pharmaceutically acceptable salt thereof as an active ingredient, and sodium hydrogen carbonate as disintegrant.
- Salts of the active compound in accordance with the present invention include but are not limited to the tartrate salt, mesylate salt, succinate salt, maleate salt, esylate salt, acetate salt, sulphate salt, phosphate salt, hydrobromide salt, hydrochloride salt, tosylate salt, benzoate salt, hexanoate salt, octanoate salt, gluconate salt, aspartate salt, and citrate salt.
- the formulation is suitable for any polymorphic forms, and in particular the polymorphic forms other than Form II, that have proven difficult to successfully formulate commercially.
- the linezolid in the formulation of the invention is in some embodiments of form I, form II, form III, form IV, amorphous form, or in certain embodiments a mixture of any two or more of these forms.
- Sodium hydrogen carbonate is the monosodium salt of carbonic acid, also referred to as sodium bicarbonate, with the formula NaHC0 3 .
- linezolid is susceptible to alkaline degradation, compatability with sodium hydrogen carbonate was tested and found fully acceptable.
- the invention is suitable for conventional (non- effervescent) tablet dosage forms.
- Conventional tablet forms can be described in the context herein as those tablet forms that disintegrate in less than 60 minutes and preferably less than 30 minutes, but typically in more than 2 minutes or 5 minutes (when tested with conventional disintegration protocols. Tablet dosage form with such characteristics are comprised as embodiments of the present invention.
- Conventional tablets include tablets that are intended for swallowing and the dosage forms of the present invention are preferably of such type.
- a tablet of the tablet formulation of the present invention may comprise in certain embodiments in the range of about 400 mg to about 1000 mg linezolid, such as 400, 500, 600 or 750 mg. 600 mg is the presently preferred dosage size.
- a tablet with a high weight proportion of the active ingredient such as in the range of about 40-80%, such as in the range of about 60%-80% such as in the range of about 65-75 wt%, for example about 60%, 65%, 70% or 75%.
- a tablet of the present formulation can in some embodiments have a total core weight (excluding optional coating) in the range of 700-1200 mg and typically in the range 800-1000 mg.
- the tablets are coated; when the tablet is coated, the coating generally adds about 2-4 wt% to the weight of the core.
- a coated tablet with a core weight of about 840 mg will have total weight of about 860-875 mg.
- any suitable coating may be applied in the present invention.
- Preferred coating materials include mixtures of hydroxypropyl methylcellulose (HPMC; hypromellose) and copovidone (copolymer of l-vinyl-2-pyrrolidone and vinyl acetate in the mass proportion 3:2), suitably together with polyethylene glycol as plasticiser.
- HPMC hydroxypropyl methylcellulose
- copovidone copolymer of l-vinyl-2-pyrrolidone and vinyl acetate in the mass proportion 3:2
- Aquarius Preferred HSP218011 is an example of such material.
- the formulation comprises in preferred embodiments a filler or diluent, which can be selected from several alternatives well known in the art.
- Suitable diluents or fillers include one or more of lactose, sucrose, glucose, sorbitol, dextrates, dextrins, dextrose, fructose, mannitol, sorbitol, starch, carboxymethylcellulose calcium, microcrystalline cellulose (MCC), powdered cellulose, sodium chloride and mixtures thereof.
- MMC microcrystalline cellulose
- microcrystalline cellulose is selected as the most preferred filler.
- the tablets of the invention will generally contain a large relative amount of the active ingredient, there is accordingly relatively little filler used when filler is incorporated.
- microcrystalline cellulose is used as filler, in the range of about 5-20 wt% of the tablet core, preferably in the range of about 7-15 wt%, such as in the range of about 8-12 wt%, or about 8 wt%, about 9 wt%, about 10 wt%, about 11 wt% or about 12 wt%.
- a binder is preferably comprised in the formulation, which can be selected from e.g. methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxymethylpropyl cellulose, polyvinylpyrrolidone (povidone), and polyvinylalcohol. Hydroxypropyl cellulose is preferred as binder.
- the tablet formulation comprises as mentioned sodium hydrogen carbonate as disintegrant.
- the amount of sodium hydrogen carbonate can be suitably in the range of 5-15 wt%, such as in the range of 5-10 wt%, such as about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt% or about 10 wt%. The amount used may depend on whether further disintegrant substances are used.
- the composition comprises in certain embodiments a further disintegrant, in particular this further disintegrant can in be some embodiments carboxymethyl cellulose, sodium starch glycolate or a combination of both.
- Carboxymethyl cellulose is preferably used in the range of about 3-8 wt% of the core weight, such as in the range of about 4-6 wt%, such as about 3 wt%, about 4 wt% or about 5 wt%.
- Sodium starch glycolate is preferably included in the composition in the range of about 2-5 wt%, such as in the range of about 2-4 wt%, such as about 3 wt%, 4 wt% or about 5 wt%.
- both substances can preferably be used in a weight ratio in the range of about 3 : 1 to about 1 : 1, such as more preferably in a ratio in the range from about 2: 1 to 1 : 1, such as in the ration of about 2: 1, about 5 :3 (1.67: 1), or about 3:2 (1.5: 1).
- the tablet formulation of the invention is suitably formulated with wet granulation. Water or an aqueous solution is preferred as granulation liquid. In one embodiment, a portion of binder is dissolved in water and this solution is used as granulation liquid.
- 20-50 wt% of the binder such as 25 wt% or 33 wt%, can be dissolved in the granulation liquid (e.g. regular grind grain size material, suitably hydroxypropyl cellulose such as Klucel EF, or the like) and the remainder, which is preferably fine grind grain size material (e.g. Klucel EXF hydroxypropyl cellulose or the like) is added as dry ingredient to the granulation blend.
- the granulation liquid e.g. regular grind grain size material, suitably hydroxypropyl cellulose such as Klucel EF, or the like
- fine grind grain size material e.g. Klucel EXF hydroxypropyl cellulose or the like
- the active ingredient linezolid is contained within the granules.
- At least a portion of the filler and binder are included in the granulation blend.
- a portion of the filler material may be used in the granule blend and the remaining portion in the extragranular matrix.
- hydroxypropyl cellulose is used as binder, and is mixed in the granule blend.
- Microcrystalline cellulose is suitably filler in the embodiment, a portion of which is in the granule blend and the remainder in the extragranular matrix.
- Suitable lubricants include but are not limited to, one or more of magnesium stearate, sodium stearyl fumarate, stearic acid, colloidal anhydrous silica, synthetic aluminum silicate, magnesium oxide, calcium stearate, talc, hydrogenated castor oil, and mixtures thereof.
- Lubricant is typically added in an amounts varying in the range from about 0.1% to about 4% by weight, preferably from about 0.5 % to about 2% by weight may be used, relative to the net weight of the formulation (core weight). According to the most preferred embodiments, sodium stearyl fumarate is selected as the lubricant.
- particle size of the active ingredient or excipients is not a critical factor.
- relatively fine particle size of the active ingredient such as but not limited to Form III linezolid
- the linezolid substance has a particle size (D90 by volume) which is less than 120 ⁇ , and preferably less than 100 ⁇ , and more preferably less than 80 ⁇ , such as less than 75 ⁇ or less than 60 ⁇ .
- the D50 vale (limit which 50% of particles fall below) is preferably less than 90 ⁇ , and more preferably less than 70 ⁇ , and even more preferably less than 50 ⁇ .
- antioxidants can also be incorporated in the formulations in order to reduce or prevent oxidation of the drug compound, they may be suitably selected from one or more of butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium metabisulfate, malic acid, citric acid and ascorbic acid.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- sodium metabisulfate malic acid
- citric acid citric acid
- ascorbic acid sodium metabisulfate
- Example 1 Tablet Formulation A
- Microcrystalline cellulose (Avicel PH 102) 32.85 3.91 Hydroxypropyl cellulose (Klucel EXF) 12.6 1.5
- Microcrystalline cellulose (Avicel PH 102) 47.55 5.66
- the tablets were manufactured with wet granulation process in high shear mixer.
- Hydroxypropyl cellulose (Klucel EF) was dissolved in water and this liquid was added to linezolid, microcrystalline cellulose (intragranular portion) and hydroxypropyl cellulose (Klucel EXF) in the high shear mixer.
- the resulting granules were wet screened and dried in fluid bed drier to LOD ⁇ l% (loss on drying). Dried granules were screened and blended with extragranular materials in two steps without/with lubricant (sodium stearyl fumarate). Tablets were compressed in rotary tablet machine.
- Microcrystalline cellulose (Avicel PH 1( D2) 47.55 5.66
- Example 3 Stability test, tablets A and B
- the table shows results of the stability tests at 40°C / 75% RH (relative humidity). Stability results are all within limits.
- Example 5 Pilot scale batch A pilot scale batch was prepared, composition was the same as for the above formulations A and B. Manufacture was conducted under low humidity conditions (30% ⁇ 5% RH).
- Hydroxypropyl cellulose (Klucel EF) was dissolved in purified water by stirring. Linezolid, hydroxypropyl cellulose (Klucel EXF) and microcrystalline cellulose were added to high speed granulator, mixed and screened and re-blended. The active blend was granulated with HPC solution and the granules wet screened and dried in fluid bed drier until LOD (moisture scale, 5 g, 105°C) was ⁇ 1%.
- LOD moisture scale, 5 g, 105°C
- Dry granules were blended with pre-screened sodium hydrogen carbonate, microcrystalline cellulose, croscarmellose sodium and sodium starch glycolate in IPC Blender.
- the blend was lubricated with pre-screened sodium stearyl fumarate.
- Tablets were compressed on rotary tablet machine.
- Tooling used was 9.3 x 19 mm oval normal concave with embossing L and 600.
- Tablets were packed in al/al blisters and HDPE (Duma) containers with two desiccant canisters.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une formulation de comprimé pharmaceutique comprenant du linézolide ou un sel de celui-ci comme principe actif. La formulation comprend une charge qui est de préférence de la cellulose microcristalline, et de l'hydrogénocarbonate de sodium comme désintégrant. Dans certains modes de réalisation, le désintégrant est un mélange de carboxyméthylcellulose et de glycolate d'amidon sodique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS50044 | 2013-01-29 | ||
IS050044 | 2013-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014118809A1 true WO2014118809A1 (fr) | 2014-08-07 |
Family
ID=50114466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IS2014/050001 WO2014118809A1 (fr) | 2013-01-29 | 2014-01-29 | Composition pharmaceutique comprenant du linézolide |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014118809A1 (fr) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (fr) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Agents antimicrobiens oxazolidinone a substitution oxazine et thiazine |
US6559305B1 (en) | 2000-02-02 | 2003-05-06 | Pharmacia & Upjohn Company | Linezolid—crystal form II |
WO2005035530A1 (fr) | 2003-10-16 | 2005-04-21 | Symed Labs Limited | Nouvelle forme cristalline du linezolid |
US20060111350A1 (en) | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
US20060142283A1 (en) | 2004-06-29 | 2006-06-29 | Judith Aronhime | Crystalline form IV of linezolid |
WO2007026369A1 (fr) | 2005-08-29 | 2007-03-08 | Symed Labs Limited | Nouvelle forme amorphe du linezolid |
US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
WO2010026597A1 (fr) | 2008-09-02 | 2010-03-11 | Hetero Research Foundation | Formes posologiques orales de linézolide et leurs procédés de préparation |
WO2010046933A2 (fr) * | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Compositions pharmaceutiques de linézolid à goût masqué |
-
2014
- 2014-01-29 WO PCT/IS2014/050001 patent/WO2014118809A1/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (fr) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Agents antimicrobiens oxazolidinone a substitution oxazine et thiazine |
US6559305B1 (en) | 2000-02-02 | 2003-05-06 | Pharmacia & Upjohn Company | Linezolid—crystal form II |
WO2005035530A1 (fr) | 2003-10-16 | 2005-04-21 | Symed Labs Limited | Nouvelle forme cristalline du linezolid |
US7714128B2 (en) | 2003-10-16 | 2010-05-11 | Symed Labs Limited | Crystalline form of linezolid |
US20060111350A1 (en) | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
US20060142283A1 (en) | 2004-06-29 | 2006-06-29 | Judith Aronhime | Crystalline form IV of linezolid |
US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
WO2007026369A1 (fr) | 2005-08-29 | 2007-03-08 | Symed Labs Limited | Nouvelle forme amorphe du linezolid |
WO2010026597A1 (fr) | 2008-09-02 | 2010-03-11 | Hetero Research Foundation | Formes posologiques orales de linézolide et leurs procédés de préparation |
WO2010046933A2 (fr) * | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Compositions pharmaceutiques de linézolid à goût masqué |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2136793B1 (fr) | Formulations pour comprimés contenant des sels de 8-[{1-(3,5-bis- (trifluorométhyl)phényl)-éthoxy}-méthyl]-8-phényl-1,7-diaza-spiro[4,5]- décan-2-one et comprimés | |
EP1515701B1 (fr) | Procédé de fabrication de comprimés multicouches comprenant de la thiazolidinedione et du biguanide | |
EP2777696B1 (fr) | Préparation de formes posologiques pharmaceutiques stables | |
JP2011126916A (ja) | プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用 | |
JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
JP6759390B2 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
AU2020316989B2 (en) | Pretomanid compositions | |
WO2015124995A1 (fr) | Formes galéniques solides de rivaroxaban | |
WO2012164578A1 (fr) | Compositions et procédés de préparation de formulations de nilotinib à libération immédiate | |
ES2895951T3 (es) | Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina | |
TWI418370B (zh) | 溶出安定性製劑 | |
WO2010026597A1 (fr) | Formes posologiques orales de linézolide et leurs procédés de préparation | |
JP6126780B2 (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
CN108686222B (zh) | 瑞舒伐他汀钙组合物的制备方法 | |
IES20070122A2 (en) | A process for the preparation of an orally administered unit dose tablet | |
CN103282051A (zh) | 口腔内崩解片剂 | |
WO2014118809A1 (fr) | Composition pharmaceutique comprenant du linézolide | |
JP6407085B2 (ja) | 錠剤およびその製造方法 | |
KR20210015788A (ko) | 항응고제의 신속 방출 약물 제제 및 이의 제조 방법 | |
EP4279075B1 (fr) | Composition pharmaceutique contenant de l'elagolix | |
TW201801725A (zh) | 含非晶索非那新的口服固體製劑及其製備方法 | |
CN112263569B (zh) | 一种阿莫西林胶囊及其制备方法 | |
CN100363001C (zh) | 一种莫西沙星胶囊剂及其制备方法 | |
WO2015071248A1 (fr) | Composition pharmaceutique à libération prolongée, non détournable, contenant du tapentadol | |
JP2022090391A (ja) | ミラベグロンを含む放出制御錠剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14704930 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14704930 Country of ref document: EP Kind code of ref document: A1 |